胰腺内分泌肿瘤的外科治疗

目的 提高对胰腺内分泌肿瘤的认知和诊疗水平.方法 回顾性分析1968 ～ 2005年收治的78例胰腺内分泌肿瘤患者的临床资料.结果 胰岛素瘤49例,均为良性,其中40例行单纯肿瘤摘除术(2例在腹腔镜下完成),2例在摘除的同时行胰腺空肠Roux-en-Y吻合术,7例行胰体尾切除术;胰高血糖素瘤4例,均有肝转移,行原发病灶及部分转移灶切除术;胰多肽瘤21例,恶性8例,手术切除16例,其余5例因肿瘤无法切除而放弃手术;舒血管肠肽瘤1例和胰腺类癌3例,均为恶性,行外科手术.术后均获得满意的疗效.结论 手术切除是胰腺内分泌肿瘤最为理想的治疗方法.术前定性诊断尤为重要,关键是提高对这类肿瘤的认知水平.对胰岛素瘤不强求术前定位诊断,应慎用有创性诊断方法,术中胰腺探查是定位的关键.其他内分泌肿瘤术前多可依影像学检查定位诊断.手术方式根据肿瘤生长部位而定.姑息性切除手术亦可明显缓解症状.即便是恶性肿瘤,其预后亦明显好于胰腺外分泌肿瘤.     

胰腺内分泌肿瘤的诊断及手术治疗

对28例经手术治疗、病理检查证实的胰腺内分泌肿瘤（PETs）患者的临床资料作回顾性分析。发现PETs以胰岛素瘤、胰多肽瘤最常见,肿瘤大小与症状轻重无关;胰岛素瘤体积较小,术前定位诊断较难;胰多肽瘤无特定性症状,术前定性诊断较难。本组胰岛素瘤18例,均为良性,其中15例行单纯肿瘤切除术;胃泌素瘤1例为恶性,行胰尾联合全胃切除术;胰高血糖素瘤2例均为恶性,术中发现肝转移,1例行胰体尾联合肝转移灶切除术,1例行姑息性切除;胰多肽瘤7例,4例行肿瘤切除术,3例伴肝转移者中,1例行胰体尾姑息性切除术,2例无法切除。认为PETs术前诊断比较困难;手术切除是PETs最理想的治疗方法,手术方式根据肿瘤生长部位和性质而定。     

胰岛细胞瘤64例诊治分析

回顾性分析64例经手术治疗及病理证实的胰岛细胞瘤患者的临床资料，发现患者均具有典型的Whipple三联征，61例（95．3％）术前明确定位诊断。术中见肿瘤位于胰头16例、胰体27例、胰尾21例；53例行肿瘤切除术，10例行胰体尾切除术，5例联合脾切除术、1例行胰十二指肠切除术。术后病理证实为良性60例、恶性4例。术后血糖检测逐渐恢复正常，18例出现不同程度胰瘘。47例随访3个月～3a，2例复发，再次手术后痊愈；2例恶性者分别于术后6、13个月出现肝转移及腹腔转移。认为术前准确定位诊断，术中完整、彻底切除肿瘤是治疗胰岛细胞瘤的关键。     

胰岛细胞瘤的外科诊治经验——附19例报告

目的：探讨胰岛细胞瘤的外科诊断与治疗。方法：回顾分析近5年我院手术的治疗胰岛细胞瘤的经验，总结胰岛细胞瘤临床特征，诊治方法及其效果。结果：本组19例病例中，无功能性胰岛细胞瘤8例，胰岛素瘤11例，其中2例为多发性内分泌瘤瘤，前恶变率62．5％（5／8），平均年龄40岁，后恶变率9．8％（1／11），平均年龄39岁，肿瘤位于胰头8例，胰体6例，胰尾5例，术前影像诊断明确肿瘤定位15例（78．9％），其余4例定位可疑或不能定位经术中超声和触摸探查到定位，对肿瘤行局部切除术11例，胰体尾切除＋胰空肠吻合术5例，肿瘤＋脾脏切除术2例，Whipple手术1例，术后胰瘘发生率为31．6％（6／19），是最常见的并发症，无手术死亡病例。结论：无功能性胰岛细胞瘤恶变率显高于胰岛素瘤（P＜0．01）。术前不能确定肿瘤位置的，应联合应用于中超声和术触摸以探查肿瘤部位。胰岛素瘤手术方式多为单纯肿瘤切除，无功能性胰岛细胞瘤，术中常规冰冻切片检查，对可疑恶性应尽量采取根治性手术。     

胰岛素瘤62例诊治体会

目的：总结胰岛素瘤的诊治经验，评估胰岛素瘤的多种定位诊断技术。方法：回顾性分析两院1970年-2001年来收治的62例胰岛素瘤的临床资料。结果：CT、MRI、术前B超、SAOG及IOUS诊断胰岛素瘤的敏感性分别为46.4%、70.0%、75.6%、75.9和100%；手术治疗60例，其中实施肿瘤剜除术41例，胰体尾切除术14例，胰十二指肠切除术3例，楔形切除术1例，姑息手术1例，总手术切除率98.3%；全组无手术死亡，肿瘤切除术后病人随访无低血糖发作；术后并发症包括胰瘘5例、胰腺假性囊肿2例。结论：术前B超和SAOG、术中详尽扪诊联合IOUS可基本上取得胰岛素瘤较为满意的定位诊断；根据胰岛素瘤的大小、部位、数目及性质采取适宜的手术方式是获得良好疗效的关键。     

功能性胰岛素瘤的外科临床诊疗分析

目的探讨功能性胰岛素瘤的外科诊疗方法。方法回顾性分析1990年1月至2006年12月有明显临床症状的,经手术治疗、病理证实的36例功能性胰岛素瘤患者的临床资料。结果在功能性胰岛素瘤患者中良性胰岛素瘤病例最多见,共27例,占全部病例的75%;恶性胰岛素瘤6例,胰岛细胞增殖症2例。在B超、CT、MRI、内镜超声等影像学检查中,术中B超阳性发现和定位准确率均为92.3%。所有病例均行手术治疗,7例行胰十二指肠切除术,17例行胰体尾切除术,12例行单纯瘤体摘除术,术后症状改善明显,复发率低。结论术中B超是诊断和定位胰岛素瘤最有效的诊断方法,手术规范切除是治疗功能性胰岛素瘤的有效方法,其预后良好。     

功能性胰岛素瘤的外科临床诊疗分析

目的 探讨功能性胰岛素瘤的外科诊疗方法.方法 回顾性分析1990年1月至2006年12月有明显临床症状的,经手术治疗、病理证实的36例功能性胰岛素瘤患者的临床资料.结果 在功能性胰岛素瘤患者中良性胰岛素瘤病例最多见,共27例,占全部病例的75%;恶性胰岛素瘤6例,胰岛细胞增殖症2例.在B超、CT、MRI、内镜超声等影像学检查中,术中B超阳性发现和定位准确率均为92.3%.所有病例均行手术治疗,7例行胰十二指肠切除术,17例行胰体尾切除术,12例行单纯瘤体摘除术,术后症状改善明显,复发率低.结论 术中B超是诊断和定位胰岛素瘤最有效的诊断方法,手术规范切除是治疗功能性胰岛素瘤的有效方法,其预后良好.     

胰岛素瘤62例诊治体会

目的总结胰岛素瘤的诊治经验,评估胰岛素瘤的多种定位诊断技术.方法回顾性分析两院1970年～2001年来收治的62例胰岛素瘤的临床资料.结果 CT、MRI、术前B超、SAOG及IOUS诊断胰岛素瘤的敏感性分别为46.4%、70.0%、75.6%、75.9%和100%;手术治疗60例,其中实施肿瘤剜除术41例,胰体尾切除术14例,胰十二指肠切除术3例,楔形切除术1例,姑息手术1例,总手术切除率98.3%;全组无手术死亡,肿瘤切除术后病人随访无低血糖发作;术后并发症包括胰瘘5例、胰腺假性囊肿2例.结论术前B超和SAOG、术中详尽扪诊联合IOUS可基本上取得胰岛素瘤较为满意的定位诊断;根据胰岛素瘤的大小、部位、数目及性质采取适宜的手术方式是获得良好疗效的关键.     

胰岛细胞瘤的外科诊治经验--附19例报告

目的探讨胰岛细胞瘤的外科诊断与治疗.方法回顾分析近5年我院手术治疗胰岛细胞瘤的经验,总结胰岛细胞瘤临床特征、诊治方法及其效果.结果本组19例病例中,无功能性胰岛细胞瘤8例,胰岛素瘤11例,其中2例为多发性内分泌腺瘤.前者恶变率62.5%(5/8),平均年龄40岁;后者恶变率9.8%(1/11),平均年龄39岁.肿瘤位于胰头8例,胰体6例,胰尾5例.术前影像诊断明确肿瘤定位15例(78.9%),其余4例定位可疑或不能定位者经术中超声和触摸探查得到定位.对肿瘤行局部切除术11例,胰体尾切除+胰空肠吻合术5例,肿瘤+脾脏切除术2例,Whipple手术1例.术后胰瘘发生率为31.6%(6/19),是最常见的并发症,无手术死亡病例.结论无功能性胰岛细胞瘤恶变率显著高于胰岛素瘤(P<0.01).术前不能确定肿瘤位置的,应联合应用术中超声和术者触摸以探查肿瘤部位.胰岛素瘤手术方式多为单纯肿瘤切除;无功能性胰岛细胞瘤,术中常规冰冻切片检查,对可疑恶性者应尽量采取根治性手术.     

胰腺神经鞘瘤50例

目的:分析胰腺神经鞘瘤的特点并探讨其诊治方法.方法:对文献上报告的49例及我院收治的1例胰腺神经鞘瘤患者的临床特点进行回顾性分析.结果:胰头病变25例,胰体9例,胰体/尾部6例,胰尾部5例,胰头/体部2例,定位不明的2例,胰颈部1例.实性肿物18例,囊性25例,7例患者肿瘤的性质不能确定.49例患者手术切除,胰十二指肠切除术13例,远端胰腺切除术12例,肿物局部切除术12例,单纯肿物核除术8例,术式不明2例,肿物无法切除1例,活检1例,拒绝手术1例.随访时间最长的达到9a,无肿瘤复发和转移.结论:胰腺神经鞘瘤术前诊断困难,绝大部分为良性,恶性少见,确诊靠病理,良性者可行肿瘤核除术,恶性者可根治性切除,术中快速病理切片有助于决定手术方式.     

Laparoscopic surgery of pancreas

In pancreatic diseases, laparoscopic surgery is used to drain fluid collections in infected pancreatic necrosis, abscesses and pseudocysts, for cancer staging, to resect both benign and malignant tumors and for palliative procedures as well. In patients with intractable pain, percutaneous or surgical celiac plexus block can be performed, celiac ganglion alcoholization and torachoscopic splacnicectomy can be done. The laparoscopic approach for staging, allows us to identify very small peritoneal or hepatic metastasis, local invasion or deep hepatic metastasis. The lack of tactile sensation is a disadvantage in the laparoscopic procedures for both staging and resection; which can be compensated utilizing laparoscopic ultrasound. The laparoscopic pancreatic approach for resection is useful to treat neuroendocrine tumors, chronic pancreatitis and cystic neoplasm allowing preservation of the splenic vessels and the spleen. The insulinoma is a treatable laparoscopic tumor given its unique characteristics. The preoperative diagnosis is made by image studies like ultrasound, CAT scans, angiography studies, MRI, endoscopic ultrasound and calcium stimulation test. There are three surgical options: enucleation, distal pancreatectomy with or without preserving the spleen. The most important complication is the pancreatic fistula. CONCLUSIONS: The laparoscopic approach in pancreatic surgery is a feasible and safe one, although, its superiority over the classic open approach has not been demonstrated yet.     

EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified

BACKGROUND: Pancreatic endocrine tumors (PETs) are rare (1 per 100,000 population) and are thought to be functioning in up to 85% of cases and are generally less than 2 cm in size. By previous reports, 15% to 50% of PETs are nonfunctioning and are discovered either incidentally or by symptom evaluation from a mass effect. EUS-guided FNA (EUS-FNA) has been shown to accurately diagnose PETs and to localize tumors for surgical resection. OBJECTIVE: To describe a single-center experience of EUS-FNA diagnosis of PETs and its impact on surgical management. DESIGN: Retrospective cohort study. SETTING: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. PATIENTS: Patients with PETs diagnosed via EUS-FNA over a 4-year period were identified through the authors' EUS database. Clinical history, laboratory values, diagnostic studies, EUS findings, cytology, pathology, operative records, and surgical pathology records were reviewed. MAIN OUTCOME MEASUREMENT: Impact of definitive preoperative diagnosis of PET on surgical management. RESULTS: Forty-one patients were diagnosed by EUS-FNA with PET. Thirty-five PETs were nonfunctioning PET; 6 were functioning PET. The mean tumor sizes of functioning and nonfunctioning PETs were 19 mm and 28 mm, respectively. The majority of tumors were located in the pancreatic head. Surgery was performed in 78% of patients; of these, 34% were resected laparoscopipcally. LIMITATIONS: Retrospective design and selection bias. CONCLUSIONS: In this study, nonfunctioning PETs were more commonly diagnosed compared with functioning PETs. In addition, the PETs were smaller than previously reported, likely because of increasing detection of incidental lesions through widespread use of abdominal imaging.     

Determinants of surgical resection for pancreatic neuroendocrine tumors

Pancreatic neuroendocrine tumors (pNETs) include functioning and non‐functional tumors. Functioning tumors consist of tumors that produce a variety of hormones and their clinical effects. Therefore, determinants of resection of pNETs should be discussed for each group of tumors. Less than 10% of insulinomas are malignant, therefore more than 90% of the cases can be cured by surgical resection. Lymphadenectomy is generally not necessary in insulinoma operation. If preoperative localization of the insulinoma is completed, enucleation from the pancreatic body or tail, and distal pancreatectomy can be performed safely by laparoscopy. When preoperative localization of a sporadic insulinoma is not confirmed, surgical exploration is needed. Intraoperative localization of a tumor, intraoperative insulin sampling and frozen section are required. The crucial purpose of surgical resection is to control inappropriate insulin secretion by removing all insulinomas. Gastrinomas are usually located in the duodenum or pancreas, which secrete gastrin and cause Zollinger‐Ellison syndrome (ZES). Duodenal gastrinomas are usually small, therefore they are not seen on preoperative imaging studies or endoscopic ultrasound, and can be found only at surgery if a duodenotomy is performed. In addition, lymph node metastasis is found in 40–60% of cases. Therefore, the experienced surgeons should direct operation for gastrinomas. Surgical exploration with duodenotomy should be performed at a laparotomy. Other functioning pNETs can occur in the pancreas or in other locations. Curative resection is always recommended whenever possible after optimal symptomatic control of the clinical syndrome by medical treatment. Indications for surgery depend on clinical symptom control, tumor size, location, extent, malignancy and presence of metastasis. A lot of non‐functioning pNETs are found incidentally according to the quality improvement of imaging techniques. Localized, small, malignant non‐functioning pNETs should be operated on aggressively, while in possibly benign tumors smaller than 2 cm the surgical risk‐benefit ratio should be carefully weighted. Surgical liver resection is generally proposed in curative intent to all patients with operable metastases from G1 or G2 pNET. The benefits of surgical resection of liver metastases have been demonstrated in terms of overall survival and quality of life. Complete resection is associated with better long‐term survival.     

Rare endocrine tumours of the GI tract

Functional pancreatic endocrine tumors other than gastrinoma and insulinoma are quite rare. The principles of management include the diagnosis and management of the functional hormonal syndrome, and management of the potentially malignant tumor. Optimally, control of the hormonal syndrome is achieved preoperatively to stabilize the patient status for the operation, however, resection may be an important part of the control of the hormonal syndrome. Ultimately, the only curative treatment for these neoplasms is complete tumour resection, when feasible.     

67-jährige Patientin mit rezidivierenden Hypoglykämien

A 67 year old female patient was admitted to our clinic with recurrent hypoglycemia in December 2006. Laboratory findings revealed an elevated insulin, and C-peptide. Imaging techniques revealed a tumor of the pancreas involving the spleen with metastases of the liver, expressing somatostatin receptors. Ultrasound-guided biopsy was performed and confirmed the suspected insulinoma. Since the hypoglycemias could not sufficiently be controlled by subcutaneous administration of octreotide and by oral glucose intake, surgical debulking was performed in a palliative intention. After resection the patient was free of hypoglycemia. In case of diagnosed insulinoma, underlying MEN (multiple endocrine neoplasia) should be considered. Excision of the tumor is recommended in patients with benign solitary insulinomas. If complete excision is impossible, there are several therapeutic options that aim at preventing hypoglycemia. Thus, in contrast to other extended tumors, surgery is reasonable in malignant insulinoma even in case of metastatic disease.     

Laparoscopic surgical treatment of insulinomas with the use of intraoperative ultrasonography

BACKGROUND: Insulinoma are insulin productive tumors originated from the pancreatic beta cells with an incidence of 4/1 million persons. It is more prevalent between the 5th and 6th decade, in women (2:1) and from the endocrine pancreatic tumor is the more frequent (50% to 60%). Insulinoma behave as a benign tumor when the diameter is inferior to 2 cm. The diagnosis is mainly clinical and laboratorial. Surgery is the unique treatment with potential cure. AIM: The present observation reports the use of simultaneous laparoscopic resection associated to intraoperative ultrasonography. METHODS: Five patients were studied (3 man and 2 women) with age from 20 to 53 years old, clinically diagnosed with insulinoma. After image work out it was proposed nuclear resection of the insulinoma by laparoscopic technique associated to intraoperative ultrasonography. RESULTS: The patients had a complete remission of tumor related hypoglycemia and one patient developed a pancreatic fistula and other a pancreatic pseudocist with good postoperative resolution. CONCLUSIONS: The videolaparoscopic approach for the surgical treatment of insulinoma is feasible. The intraoperative ultrasonography helps to identify the lesions and check their complete resection with low complication rate.     

Insulinoma: diagnostic strategies and surgical treatment. A 22-year experience.

BACKGROUND/AIMS: The efficacy of preoperative localization methods and the results of the surgical treatment of insulinoma were studied. METHODOLOGY: Fifty-nine patients referred for surgical treatment were studied and the results of the diagnostic tools for tumor localization were compared with findings at surgical intervention. The influence of the type of surgical procedure in the immediate and late postoperative course was also studied. RESULTS: Ultrasonography had a sensitivity of 30%, computed tomography 25%, angiography 54%, portal vein sampling 94%, endoscopic ultrasonography 27% and magnetic resonance 17%. Intraoperative palpation localized 98.2% of the tumors and by the addition of intraoperative echography, all lesions were identified. In 55 patients with benign lesions, 22 enucleations, 25 distal pancreatectomies, 7 pancreatectomies plus enucleation and one duodenopancreatectomy were performed. Malignant tumors were treated by pancreatic resection, postoperative hepatic artery embolization and systemic chemotherapy. There was no postoperative mortality. Pancreatic fistula was the most common complication. Three patients who underwent distal pancreatectomy developed late diabetes (9.3%). CONCLUSIONS: Extensive preoperative investigation, mainly with invasive methods, is not indicated and by combining intraoperative palpation and echography most of the cases can be adequately dealt with. Preservation of pancreatic tissue with enucleation and preservation of the spleen are the best choice for treatment of benign insulinomas.     

Occult sporadic insulinoma： Localization and surgical strategy

Insulinomas continue to pose a diagnostic challenge to physicians, surgeons and radiologists alike. Most are intrapancreatic, benign and solitary. Biochemical diagnosis is obtained and imaging techniques to localize lesions continue to evolve. Surgical resection is the treatment of choice. Despite all efforts, an occult insulinoma （occult insulinoma refers to a biochemically proven tumor with indeterminate anatomical site before operation） may still be encountered. New localization preoperative techniques decreases occult cases and the knowledge of the site of the mass before surgery allows to determine whether enucleation of the tumor or pancreatic resection is likely to be required and whether the tumor is amenable to removal via a laparoscopic approach. In absence of preoperative localization and intraoperative detection of an insulinoma, blind pancreatic resection is not recommended.     

Pancreatic insulinomas: diagnosis and treatment

BACKGROUND: Despite its rarity, the insulinoma is the most common pancreatic neuroendocrine tumor. OBJECTIVE: Analyze clinical and immunohistochemical data from surgical resection of the pancreas insulinoma. METHOD: Twelve cases are described, concerning surgical aspects, complications and medium-long term outcome of patients. They underwent surgical treatment due to clinical suspicion and biochemical diagnosis of hypoglycemia and hyperinsulinism. RESULTS: The insulinoma was identified preoperatively in seven patients, while intraoperative ultrasonography and palpation were necessary for diagnosis in the other cases. Eight patients underwent pancreatic resection and pancreatic leak was observed in seven cases. Two patients developed diabetes mellitus and no mortality occurred in the current series. CONCLUSION: All patients presented satisfactory outcome and remained asymptomatic with normal glicemia levels.     

Telomerase activity in pancreatic endocrine tumors

OBJECTIVES: Pancreatic endocrine tumors (PETs) have variable prognoses, and predictors of survival are lacking. PETs can be difficult to distinguish histologically from aggressive pancreatic neoplasms such as acinar cell carcinoma. Telomerase is a ribonuclear protein that maintains the length of the telomere and induces cell immortality. Telomerase is present in 95% of pancreatic adenocarcinoma and is associated with aggressive tumor behavior. Our aim is to determine telomerase activity in PETs and investigate its potential role as a prognostic indicator. METHODS: Telomerase detection using the telomeric repeat amplification protocol was performed on frozen surgical archived pancreatic endocrine tissue from 30 patients with PETs identified by light microscopy (hematoxylin-eosin stain). All results were confirmed with internal controls. A patient's survival was measured from the time of surgery. Acinar cell differentiation (presence of zymogen granules) was determined by electron microscopy. Follow-up data were acquired via telephone interview, medical record review, and death certificates. RESULTS: Three of 30 PETs diagnosed by light microscopy were telomerase positive: three were considered nonfunctional, and two of these three patients had extrapancreatic disease. All three telomerase-positive cases were reclassified as either acinar cell carcinoma (two cases) or mixed acinar-endocrine cell carcinoma (one case). All three patients (mean age = 63 yr) died from tumor progression within 2 yr of surgery (mean = 1.6 yr +/- 0.5 SD). The remaining PETs were telomerase negative: 13 insulinomas, four nonfunctional, two sporadic glucagonomas, one gastrinoma, one vipoma, one carcinoidlike PET, and five PETs from three patients with multiple endocrine neoplasm syndrome type I and two patients with von Hippel-Lindau syndrome. Excluding insulinomas, 12 of 14 patients with telomerase-negative PETs had extrapancreatic disease. Nevertheless, Kaplan-Meier survival estimates for these 12 patients were significantly longer than for patients with telomerase-positive acinar cell carcinoma (92% vs 0% at 2 yr, p = 0.001, log rank test). The survival of all telomerase-negative PETs (n = 27) was significantly longer than that of the patients with telomerase-positive acinar cell carcinoma (93% vs 0% at 2 yr, p = 0.0001). CONCLUSIONS: Telomerase activity helps to identify acinar cell carcinomas that histologically resemble PETs, which accounts for the poor prognosis demonstrated in these patients. The absence of telomerase activity in most PETs may be responsible for their indolent clinical course. Telomerase may identify potentially progressive tumors, such as acinar cell carcinoma, and may be useful in selecting patients for more aggressive treatment.